The FDA has begun embracing real-world evidence (RWE) as supportive data for diagnostics and device approvals. Sponsors who integrate RWE strategies early can de-risk pivotal trials and accelerate timelines.
Decentralized & Hybrid Trials
Hybrid models, combining remote elements with traditional sites, are reshaping diagnostics and medical device research. These designs expand access, speed enrollment, and produce more represent data.
AI in Clinical Trials
AI-driven site selection, patient matching, and data checks are making trials faster and smarter. With the FDA exploring AI/ML in device development, sponsors who adopt early gain a competitive edge.
Regulatory Agility for Diagnostics
Programs like Breakthrough Device and Safer Technologies can shorten timelines. Aligning study design and endpoints early with these pathways improves speed and predictability.
Patient Diversity by Design
Regulators expect inclusive enrollment. Planning for diversity up front improves evidence quality, credibility, and real-world relevance for diagnostics and devices.
Specimen & Lab Readiness
Tight chain-of-custody, fit-for-purpose comparators, and clear lab oversight are critical in diagnostic trials. Getting these right prevents rework and protects timelines.
You are leaving this site
You're about to visit an external website. Do you wish to continue?
